Cancer gene therapy - State-of-the-art

Reports of Practical Oncology and Radiotherapy

Volumn 7, Issue 4, 2002, Pages 149-155

  Wysocki, Piotr J ^a   Mackiewicz Wysocka, M ^a   Mackiewicz, Andrzej ^a  

^a Chair of Oncology   (Poland)

Author keywords

Antiangiogeic therapy; Cancer gene therapy; Immnotherapy; Suicide therapy; Viral vectors

Indexed keywords

EID: 84859878207     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1507-1367(02)70989-9     Document Type: Review

References (40)

1. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000;38:208-17.
2. Johnen H, Kulbe H, Pecher G. Long-term tumour growth suppression in mice immunized with naked DNA of the human tumour antigen mucin (MUC1). Cancer Immunol Immunother 2001;50:356-60.
3. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumour immunity against human papillomavirus type 16 E7-expressing murine tumour metastases in the liver and lungs. Gene Ther 1999;12:1972-81.
4. Novakovic S, Knezevic M, Golouh R, Jezersek B. Transfection of mammalian cells by the methods of receptor mediated gene transfer and particle bombardment. J Exp Clin Cancer Res 1999;18:531-6.
5. Suzuki S, Tadakuma T, Kunitomi M, Takayama E, Sato M, Asano T, et al. Liposome-Mediated Gene Therapy Using HSV-TK/Ganciclovir under the Control of Human PSA Promoter in Prostate Cancer Cells. Urol Int 2001;67:216-23.
6. Leonetti C, Biroccio A, Benassi B, Stringaro A, Stoppacciaro A, Semple SC, et al. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoural efficacy in vivo in a human melanoma line. Cancer Gene Ther 2001;8:459-68.
7. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumour-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-8.
8. Gilboa E, Kolbe M, Noonan K, Kucherlapati R. Construction of a mammalian transducing vector from the genome of Moloney murine leukemia virus. J Virol. 1982;44:845-51.
9. Rother RP, Squinto SP, Mason JM, Rollins SA. Protection of retroviral vector particles in human blood through complement inhibition. Hum Gene Ther. 1995;6:429-35.
10. The Journal of Gene Medicine Clinical Trial site http://www.willey.com/genetherapy/clinical
11. Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI, et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997;57:19-25.
12. Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, et al. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 1996;70:4173-8.
13. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998;95:7866-71.
14. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 2000;7:20-3.
15. Yang S, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999;10:123-32.
16. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumour-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A;98:10290-5.
17. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, et al. CancerVax, an allogeneic tumour cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001;8:389-401.
18. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
19. Van Gool SW, Zhang Y, Kasran A, de Boer M, Ceuppens JL. T helperindependent activation of human CD8+ cells: the role of CD28 costimulation. Scand J Immunol 1996;44:21-9.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;6673:245-52.
21. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-80.
22. Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, Kaczmarek A, Laciak M, Czapczyk A, Karczewska A, Rose-John S, Mackiewicz A. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett. 2000;74:81-6.
23. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, et al. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 2000;7:247-54.
24. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001; 7:23-31.
25. Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, et al. Intratumoural adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001;4:182-91.
26. Zhang R, Straus FH, DeGroot LJ. Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid 2001;11:115-23.
27. Carrio M, Mazo A, Lopez-Iglesias C, Estivill X, Fillat C. Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. Int J Cancer 2001;94:81-8.
28. Kapcińska M, Wysocki P, Wiznerowicz M, Mackiewicz A. Enhancement of suicide effect of herpes simplex thymidine kinase gene by IL-6 and GM-CSF genes. Wspol Onkol 1999;5:191-4.
29. Xu M, Kumar D, Srinivas S, Detolla LJ, Yu SA, Stass SA, et al. Parenteral gene therapy with p53 inhibits human breast tumours in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1997;8:177-85.
30. Obermiller PS, Tait DL, Holt JT. Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies. Breast Cancer Res 2000;2:28-31.
31. Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 1997;11:1959-68.
32. Calbo J, Marotta M, Cascallo M, Roig JM, Gelpi JL, Fueyo J, et al. Adenovirusmediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 2001;10: 740-50.
33. Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 2000;7:360-72.
34. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoural efficacy. Nat Med 2000;10: 1134-9.
35. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000;56: 6660-9.
36. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7.
37. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos, GD, et al. Antiangiogenic gene therapy targeting the endotheliumspecific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998;95; 8829-34.
38. Gorrin-Rivas MJ, Arii S, Mori A, Kaneda Y, Imamura M. Mouse macrophage metalloelastase gene delivery by HVJ-cationic liposomes in experimental antiangiogenic gene therapy for murine CT-26 colon cancer. Int J Cancer 2001;93:731-5.
39. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000;60:1503-6.
40. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillepsie GY, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumour growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998;95:8795-800.